Quebec drug developer Labopharm Inc. (TSX:DDS) has entered into an agreement providing it with up to $25 million of capital over the next three years through the purchase of newly issued common shares. Labopharm's stock was up 11 cents, or seven per cent, to $1.65, on the Toronto Stock Exchange.